Occurrence of concurrent infections with multiple serotypes of dengue viruses during 2013 to 2015 in northern Kerala, India

Manchala Nageswar Reddy ¹, Ranjeet Dungdung ¹, Lathika Valliyott ¹, Rajendra Pilankatta Corresp. ²

¹ Department of Biochemistry and Molecular Biology, Central University of Kerala, kasargod, kerala, India
² Department of Biochemistry and Molecular Biology, Central University of Kerala, kasargod, kerala, India

Corresponding Author: Rajendra Pilankatta
Email address: praj74@cukerala.ac.in

Background: Dengue is a global human public health threat, causing severe morbidity and mortality. The occurrence of sequential infection by more than one serotype of dengue virus (DENV) is a major contributing factor for the induction of Dengue hemorrhagic fever [DHF] and Dengue shock syndrome [DSS], two major medical conditions caused by DENV infection. However, there is no specific drug or vaccine available against dengue infection. There are reports indicating the increased incidence of concurrent infection of dengue in several tropical and subtropical regions. Recently, increasing number of DHF and DSS cases were reported in India indicating potential enhancement of concurrent DENV infections. Therefore, accurate determination of the occurrence of DENV serotype co-infections needs to be conducted in various DENV prone parts of India. In this context, the present study was conducted to analyse the magnitude of concurrent infection in northern Kerala, a southwest state of India, during three consecutive years from 2013 to 2015.

Methods: A total of 120 serum samples were collected from the suspected dengue patients. The serum samples were diagnosed for the presence of dengue NS1 antigen followed by the isolation of dengue genome from NS1 positive samples. The isolated dengue genome was further subjected to RTPCR based molecular serotyping. The phylogenetic tree was constructed based on the sequence of PCR amplified products.

Results: Out of the total number of samples collected, 100 samples were positive for dengue specific antigen (NS1) and 26 of them contained the dengue genome. The RTPCR based molecular serotyping of the dengue genome revealed the presence of all four serotypes with different combinations. However, serotypes 1 and 3 were predominant combinations of concurrent infection. Interestingly, there were two samples with all four serotypes concurrently infected in year 2013. Discussion: All samples containing dengue genome showed the presence of more than one serotype, indicating 100 % concurrent infection. However, the combination of serotypes 1 and 3 was predominant. To the best of our knowledge, this is the first report indicating the concurrent infection of dengue in the...
northern Kerala, India. The phylogenetic analysis of dengue serotype 1 identified in this study shows a close relationship with the strain isolated in Delhi and South Korea during the 2006 and 2015 epidemics respectively. Similarly this study indicates that the phylogeny of dengue serotype 3 of northern Kerala is more closely related to dengue isolate of Rajasthan state, India. The geographical and climatic conditions of Kerala favours the breeding of both the mosquito vectors of dengue (Aedes albopictus and Aedes aegypti), which may enhance the severity of dengue in the future. Therefore, the study provides an alarming message for the urgent need of an antiviral strategy or other health management systems to curb the spread of dengue infection.
Occurrence of concurrent infections with multiple serotypes of dengue viruses during 2013 to 2015 in northern Kerala, India

Manchala Nageswar Reddy¹, Ranjeet Dungdung¹, Lathika Valliyott¹, Rajendra Pilankatta¹

¹Department of Biochemistry and Molecular Biology, School of Biological Sciences, Central University of Kerala, India

*Correspondence Author:

Rajendra Pilankatta

E-mail address: praj74@cu.kerala.ac.in.
Abstract

Background: Dengue is a global human public health threat, causing severe morbidity and mortality. The occurrence of sequential infection by more than one serotype of dengue virus (DENV) is a major contributing factor for the induction of Dengue hemorrhagic fever [DHF] and Dengue shock syndrome [DSS], two major medical conditions caused by DENV infection. However, there is no specific drug or vaccine available against dengue infection. There are reports indicating the increased incidence of concurrent infection of dengue in several tropical and subtropical regions. Recently, increasing number of DHF and DSS cases were reported in India indicating potential enhancement of concurrent DENV infections. Therefore, accurate determination of the occurrence of DENV serotype co-infections needs to be conducted in various DENV prone parts of India. In this context, the present study was conducted to analyse the magnitude of concurrent infection in northern Kerala, a southwest state of India, during three consecutive years from 2013 to 2015. Methods: A total of 120 serum samples were collected from the suspected dengue patients. The serum samples were diagnosed for the presence of dengue NS1 antigen followed by the isolation of dengue genome from NS1 positive samples. The isolated dengue genome was further subjected to RTPCR based molecular serotyping. The phylogenetic tree was constructed based on the sequence of PCR amplified products. Results: Out of the total number of samples collected, 100 samples were positive for dengue specific antigen (NS1) and 26 of them contained the dengue genome. The RTPCR based molecular serotyping of the dengue genome revealed the presence of all four serotypes with different combinations. However, serotypes 1 and 3 were predominant combinations of concurrent infection. Interestingly, there were two samples with all four serotypes concurrently
infected in year 2013. **Discussion:** All samples containing dengue genome showed the presence of more than one serotype, indicating 100% concurrent infection. However, the combination of serotypes 1 and 3 was predominant. To the best of our knowledge, this is the first report indicating the concurrent infection of dengue in the northern Kerala, India. The phylogenetic analysis of dengue serotype 1 identified in this study shows a close relationship with the strain isolated in Delhi and South Korea during the 2006 and 2015 epidemics respectively. Similarly, this study indicates that the phylogeny of dengue serotype 3 of northern Kerala is more closely related to dengue isolate of Rajasthan state, India. The geographical and climatic conditions of Kerala favours the breeding of both the mosquito vectors of dengue (*Aedes albopictus* and *Aedes aegypti*) which may enhance the severity of dengue in the future. Therefore, the study provides an alarming message for the urgent need of an antiviral strategy or other health management systems to curb the spread of dengue infection.
**Introduction**

Dengue virus (DENV) belongs to the family of Flaviviridae and genus *Flavivirus* and poses a global threat resulting in significant morbidity and mortality. The virus is transmitted by day-biting mosquito, *Aedes aegypti* (Liu et al., 2014). However, there is no vaccine or antiviral drug available that can neutralize all the four serotypes of dengue viruses.

There are four distinct DENV1-4 serotypes circulating all over the world and causing DENV infection. The infection causes symptoms ranging from acute febrile illness to severe manifestations, including bleeding and organ failure resulting in the DHF or DSS (Gubler et al., 1998; Moi et al., 2016). Co-infection with circulating DENV 1 and DENV 2 was reported in the year 1982 in Columbia (Gubler et al., 1985). It has been known that sequential infection of more than one serotype of dengue increases the severity of dengue symptoms (Hammon et al., 1973). Meanwhile, there are reports indicating concurrent infection of dengue with more than one serotype (Anoop et al., 2010). However the correlation between concurrent infection of dengue with more than one serotype and severity of the disease symptoms is not well established. In this context, the current study becomes highly relevant and gives a platform for future investigation to understand the severity of the disease and concurrent infection caused by different dengue serotypes.
In the last 50 years, co-circulation of dengue serotypes was reported in South Asia, including India. The first virologically confirmed dengue case was reported in the east coast of Calcutta, India during 1963-64 (Carey et al., 1967; Sarkar et al., 1964). In addition, a dengue outbreak at Kanpur, India was documented during the year 1968 by DENV 4 (Chaturvedi et al., 1970). The presence of DENV 3 was found in patients as well as A.egypti mosquitoes in Vellore, India in 1966, and since then all the four types of DENV have been co-circulated and isolated from patients and mosquitoes (Myers et al., 1967; Wenming et al., 2005).

In 1996, DENV 2 serotype infections were noticed in India, followed by spreading all over the country (Shah et al., 2004; Singh et al., 2000). The capital city of India, Delhi, became a hyperendemic by hosting all four dengue virus serotypes by the year 2003 (Dar et al., 2003) with the coinfection of DENV 1 and DENV 3 in year 2005 (Gupta et al., 2006). The magnitude of concurrent infection (19%) observed during the Delhi outbreak in 2006 is much higher in comparison with Taiwan (9.5%) and Indonesia (11%). Furthermore, replacement of DENV 2 and 3 with DENV 1 as the predominant serotype in Delhi over a period of three years (2007-2009) has been reported.

The occurrence of dengue fever was reported in the Kottayam district of Kerala, a south-western region of India, followed by an outbreak in year 2003. Concurrent infection with all three DENV 1-3 were reported in a large number of patients in year 2008 (Anoop et al., 2010) in Ernakulam district, a central region of Kerala. In year 2013, various parts of India, including Davangere and Central Karnataka out of 123 positive NS1 antigen samples 56(45.5%) were infected with dengue fever, 37(30.1%) with DHF, and 30(24.4%) with DSS (Kalappanvar et al., 2013).

Since dengue cases are increasing at an alarming rate and causing a major health threat in tropical countries, it is necessary to identify and confirm the viral serotypes through
epidemiological surveillance studies. The present study was conducted in order to specifically identify dengue virus and to assess the concurrent infection in the northern Kerala (Malabar region), India during three consecutive years (2013-2015). Some of these areas are ideal ecosystems for the proliferation of *Aedes albopictus* mosquitoes. In this study, NS1 positive samples were further tested by amplification of the junction region of capsid and premembrane gene (CprM) of the dengue viral genome (Lanciotti et al., 1992) by single step reverse transcriptase polymerase chain reaction (RT-PCR) followed by specific serotype identification.

To the best of our knowledge, we are reporting for the first time the 100% concurrent infection by different dengue serotypes among the samples analysed, including two samples which were positive for all four dengue serotypes.
Patients and Methods

Sample collection: The viremic blood samples from patients with suspected dengue symptoms (as per WHO guidelines) were collected from the Government hospital and local diagnostic centres located in the northern Kerala, India. The Institutional Ethics committee (IEC) clearance (O.R.No:IAD/IEC/13/14) was taken from the Institute of Applied Dermatology (IAD), Kasaragod district, Kerala for conducting this study. The prior informed consent was obtained from all participating human subjects. The blood samples used in this study were collected between June and August of year 2013, 2014, and 2015 respectively. The blood samples were collected from patients who came to the diagnostic centres with a doctor’s prescription or with the suspicion (1-5 days). Donors were aged 5–60 years of either sex, including paediatrics (0-5 years old). Two millilitres of blood was collected in a vacutainer tube from each individual and serum was separated by centrifugation as per the standard procedure.

Detection of NS1 antigen by capture ELISA: The presence of NS1 antigen in the patient serum sample was screened for using a DENV specific NS1 detection Enzyme Linked
Immunosorbent Assay (ELISA) kit (Jmitra and Co., New Delhi, India). The kit contains monoclonal antibodies against NS1 coated on micro wells, which can detect NS1 antigen secreted by DENV in the infected patient. Fifty microliters of serum sample per micro well was used in the 96 well plate assay. Normal serum specimens obtained from healthy humans of same sex and age groups were included as controls.

**Isolation of dengue viral RNA:** Dengue viral RNA was extracted from NS1 positive serum samples using the pure link RNA mini kit (Invitrogen, USA) according to the manufacturer's instructions. Clarified human serum sample of 150 microliters volume was used for RNA isolation. All RNA samples were examined for their purity and concentration using Nano photometer (Thermo scientific, 2000C).

**Amplification of dengue viral CprM region by RT-PCR:** Isolated Dengue viral RNA from serum samples was subjected to single step reverse transcription polymerase chain reaction (RT-PCR) (Lanciotti et al., 1992). Ten microliters of PCR amplified product was analysed on a 1% agarose gel and the size compared with a 1Kb plus DNA ladder.

**Nested PCR:** A second round of amplification was initiated using one microliter of the above PCR product (1:100 in sterile distilled water) as a template in the subsequent nested PCR reaction. The reaction mixture contained all the components necessary for PCR amplification including D1 as a forward primer and dengue virus type-specific reverse primers TS1, TS2, TS3, and TS4 in separate individual tubes. The CprM consensus regions and each serotype-specific primers were designed as mentioned by Lanciotti et al., 1992 with slight modification of TS4 primer: 5′-CTCTGTGTCTTTAAACAAGAGA-3′. The PCR amplified products were analysed by electrophoresis on 1% agarose gel.
Nucleotide sequencing: All necessary Good Lab Practices (GLP) were employed to avoid artifacts. The precautions were taken to avoid the contamination of serum samples by bar coding of samples. The cross contamination was prevented by setting of the PCR independently in the separate tubes with pair of specific primers. The tube containing no template was also setup as a negative control. The RT-PCR product (511 bp) obtained using D1 and D2 primers was separated on the 1% agarose gel. The DNA band was eluted from the gel using Wizard gel and PCR clean up system (Promega, USA) as per the manufacturer instructions and was sequenced directly using big dye terminator V3.1 ready reaction sequencing mixture in an automated AB3500 Genetic Analyzer (Applied bio systems, Foster City, CA, USA). Additionally, nested PCR products obtained using D1 and TS1/TS3 dengue virus serotype specific primers were purified and sequenced as detailed above.

Amino Acid sequence similarity and diversity: The nucleotide sequences obtained from the above method were submitted to GenBank database (NCBI). These sequences were translated using the Expasy translation (EMBL) tool. These homologues amino acid regions were aligned with the partial or full length amino acid sequences of dengue isolates of diverse geographical locations (KP406801, EF127001, DQ285562, JQ922545, JN903581, KM403635, KR024707, KT187563, KP723473, JQ917404, JN713897) retrieved from GenBank, using BioEdit sequence alignment editor.

Molecular phylogenetic analysis of DENV 1 and DENV 3 by Maximum Likelihood method: The phylogenetic analysis was conducted independently for DENV 1 (GenBank accession no. KJ954284) and DENV 3 (GenBank accession no. KM042094) of northern Kerala with the gene sequences of dengue virus isolates of different locations available in NCBI GenBank. The percentage of the bootstrap supporting values was shown at major nodes on the tree. The tree is
drawn to scale, with branch lengths measuring the number of substitutions per site. The
reliability of the analysis was evaluated by a bootstrap test (MEGA), Tamura-Nei model (Tamura
et al., 2012). All positions containing gaps and missing data were eliminated.

Results
There were, in total, 120 serum samples of dengue infected individuals analysed between 2013
and 2015. Among these 120 samples, a total of 62 (51%) were male, 35 (29%) female, and 23
(20%) paediatric (0-5 years old) dengue cases (Figure 1). Both males and females belong to 30 –
40 years age group with an approximate ratio of 2:1. This ratio is similar with the previous
reported value (Mishra et al., 2015). There were 23 (20%) pediatric (0-5 years old) cases,
consisting of 14 males and 9 females. Out of 120 serum samples, 100 (83%) were found to be
NS1 positive, indicating the possibility of finding dengue viral RNA genome.

Dengue viral genome isolation and serotyping: Dengue viral RNA was isolated from NS1
positive serum samples, as detailed in the patients and methods section. The isolated RNA was
subjected to RT-PCR based amplification (Figure 2) using D1 and D2 primers. There was
dengue specific amplified product of size 511 bp present only in 26 samples. This observation
confirms the presence of dengue genome in these 26 samples out of 100 samples, which were
NS1 positive. The initial dengue NS1 antigen detection and the presence of identifying dengue
genome in the serum samples indicates the possibility of dengue infection. A representative gel
image, which indicates the presence of 511bp amplified product is given in Figure 3A. Out of
fifty-one NS1 positive samples in the year 2013, thirteen samples were found to be positive for
dengue genome. Similarly, there were three out of seventeen and ten out of thirty two samples
positive for dengue genome analysed during 2014 and 2015 respectively (Table I). All samples
were co-infected with more than one serotype with various combinations of serotypes as given in
Table I and Figure 3 (B, C, D).

Concurrent infection: The above amplified RTPCR product (511 bp) was used as a template for
nested PCR, using serotype specific primers as detailed in methods section. The nested PCR
analysis of dengue serotyping showed that a single individual is hosting for more than one
dengue virus serotype circulating in the blood. In all 26 samples of multiple infection, three
different serotypes co-existed in eight samples, two different serotypes co-existed in sixteen
cases, and four different serotypes co-existed in two samples. There are nine cases of
concurrent infection with DENV1 and DENV 3, seven cases with DENV 2 and DENV 3, eight
cases with DENV 1, 2 and 3, and two cases with DENV 1, 2, 3 and 4 combinations as shown in
the Table I. There was a large number of concurrent infection with DENV 1 and DENV 3. The
concurrent infection of all four serotypes is an alarming indication and needs to be investigated
in detail. The sequential infection with more than one serotype of a particular region leads to a
severe cause for eliciting antibody dependent immune response.

Nucleotide sequencing and dengue virus serotyping: The D1 and D2 primer based amplified
PCR product corresponding to CPrM region was sequenced (GenBank accession no.
KX031992) and the data confirmed the presence of dengue viral genome sequence in the
samples. The nucleotide sequence was found to be 99% similar with the existing CprM region of
DENV 3 viral strains in GenBank database. Blast analysis, using CprM junction nucleotide
sequence, showed similarity with DENV 3 isolates from Pakistan with 99% query coverage
(GenBank accession no.KF041254). Nucleotide sequencing of DENV 1 specific nested PCR
product, obtained using D1 and TS1 primer combinations, gives the size of 423 bp (GenBank
accession no. KJ954284). The corresponding amino acid sequence (1-139 aa) derived from
DEV 1 specific amplified region represents non functional poly protein partial sequence. DENV
3 specific nested PCR product using D1 and TS3 primer combinations gives the size of 235 bp
(GenBank accession no. KM042094) on a 1 % agarose gel. However, PCR amplified product of
DENV 2 and DENV 4 were the lesser in quantity, the nucleotide sequences were not obtained
with clarity.

**Amino Acid sequence diversity:** To observe any mutations, the amino acid sequence of
DENV1 was compared with the other closely related DENV 1 strains. The comparison of the
amino acid sequence (1-139 aa) of DENV 1 (CUKKE201308001; GenBank accession no.
KJ954284) with various DENV 1 isolates existing in the data base (GenBank accession no
KP406801, EF127001, DQ285562, JQ922545, JN903581, KM403635, KR024707, KT187563,
KP723473, JQ917404, JN713897) revealed an identity of 98%-99%, except for Valine (V)
which is replaced by Isoleucine (I) at 131st position as shown in Figure 4. However,
replacement of Isoleucine with Valine was reported at residue 106 of the capsid protein in the
isolates obtained from the 1997, 1998 and 2001 outbreaks in the Caribbean islands pertaining to
the Asian/American genotype (Gardella et al., 2008).
Phylogenetic analysis of DENV 1 and DENV 3: In the molecular phylogenetic analysis (Figure 5) by Maximum Likelihood method, the bootstrap support values indicates that the sequence of DENV 1 isolate (CUKKEL201308001; GenBank accession no. KJ954284) shares a common ancestor relationship with DENV 1 isolate (GenBank accession no. KP406801) and DENV 1 isolate 06/1/del2006 (GenBank accession no. EF127001) among 28 nucleotide sequences used for the analysis (Figure 5). Similarly the phylogenetic analysis (Figure 6) of dengue 3 virus isolate of Northern Kerala (CUKKEL2013/02; GenBank accession no. KM042094) indicates that this strain is closely related to Dengue virus isolate (DENV-3/DMRC/Bal87/2013) polyprotein gene, partial cds (KT239735) of Rajasthan, India.

Discussion
The surveillance of concurrent infection of multiple dengue serotypes as well as its co circulation becomes extremely important for understanding viral pathogenesis and also for developing a dengue tetravalent vaccine able to neutralize all four serotypes. There are only a few independent studies conducted on co-circulation and concurrent infection of dengue in India. These studies include the report on the concurrent infection of dengue which
was observed in Delhi in 2006 (Bharaj et al., 2008). In this outbreak, 9 out of 48 samples (19%) were identified positive for dengue virus as a concurrent infection with more than one dengue virus serotype. The concurrent infection with the involvement of three dengue viral serotypes (DENV 1, 2, and 3) at an approximate rate of 56.8% was observed in Ernakulam, Kerala state in 2008 (Anoop et al., 2010). A large outbreak of dengue fever (DF) was reported in 2007, in the locality of Indo-Myanmar boarder with the co circulation of concurrent infection of DENV 2 & 3, 1 & 3, and 1 & 4 serotypes (Khan et al., 2013).

In the year 1980, DENV 1 and 2 were first observed in Columbia. By 1994, many parts of the world, including, Bolivia, Brazil, Costa Rica, El Salvador, French Guiana, Guatemala, Honduras, Mexico, Nicaragua, Panama, Peru, Puerto Rico, Trinidad and Tobago, and Venezuela were hosting all four dengue serotypes (Loron et al., 1999). The first case of a dual infection with two dengue virus serotypes (DENV 1 and DENV 4) was reported in the serum of a 16 year old male during the 1982 outbreak in Puerto Rico (Gubler et al., 1985). Whereas in New Caledonia, DENV 1 and DENV 3 viruses were isolated from 6 patients with Dengue fever in 1989 (Laille et al., 1991). The first report of dual concurrent infection with DENV 2 and DENV 3 was observed in Chinese patients returned from Sri Lanka (Peng et al., 2005). The viremic serum samples (292 in total) collected during epidemics from Indonesia, Mexico, and Puerto Rico were tested, and 16 (5.5%) cases were found to contain two or more dengue viruses by reverse transcriptase–polymerase chain reaction (Loron et al., 1999).

Out of 100 NS1 positive samples, 26 (26%) were found to be containing dengue viral RNA and showed a target specific band (511bp) on an agarose gel. The low proportion of dengue viral genome in NS1 positive serum samples may be due to loss of intact viral genome or the degradation of dengue positive RNA sense strand while handling the samples. The serotyping of
the dengue viral RNA samples using nested PCR with sero specific primers revealed that all samples are concurrently infected with multiple serotypes. Different combinations of Dengue virus (DENV) concurrent infections including DENV 1 and DENV 3, 34% (9 cases out of 26 cases), DENV 2 and DENV 3, 27% (7 cases out of 26 cases), DENV 1,2 and 3, 31% (8 cases out of 26 cases) were observed. Further, it was also observed that two of the samples were concurrently infected with all four serotypes as shown in Table 1. However, coexistence of all four serotypes in one host needs to be authenticated by characterizing the viral genome after isolation and propagation of viruses from those serum samples. The observations indicate the possibility of enhancement of future concurrent infections, as the percentage of single serotype infection decreased and concurrent infection of multiple serotypes increased based on the current investigation. As supporting evidence, there were only 19 % of concurrent infections during 2006 (Delhi, India). However, there was a significant increase in the percentage of concurrent infections in 2009 (56.8%) in Ernakulum, India. The percentage of concurrent infection reached 100% based on the current investigation. It is also important to note that Kerala, a southwest state of India, provides an ideal ecosystem for the propagation of both the mosquito vectors (Aedes albopictus and Aedes aegypti) of dengue transmission.

Since the maximum nucleotide sequence was obtained in the case of DENV 1, the amino acid alignment (1-139 aa) was made with the various DENV 1 isolates existing in the data base, which revealed an identity of 98%-99%, except Isoleucine instead of Valine at 131st position as shown in Figure 4. Since both amino acids belong to the non polar group of standard genetic code, the amino acid change may not have any significance. Phylogenetic analysis of DENV 1 nucleotide sequences (GenBank accession no. KJ954284) obtained from 2013 epidemic samples shares a common ancestor relationship with clinical isolates of DENV 1 from South Korean
Travellers (GenBank accession no. KP406801) as well as the DENV 1 isolate from Delhi, India (GenBank accession no. EF127001) in among 28 nucleotide sequences used for the analysis (Figure 5). Similarly the phylogenetic analysis (Figure 6) of dengue 3 virus isolate of northern Kerala indicates the close relationship to Dengue virus isolate (DENV-3/DMRC/Bal87/2013) polyprotein gene, partial cds (KT239735) of Rajasthan, India. Concurrent infection of multiple serotypes of dengue poses a lot of questions regarding viral replication. The possibility of mutual interference among different dengue serotypes during replication within the same host need to be investigated in detail. If so, would there be any replicative advantage to one of the serotypes against the other three serotypes? The viral interference which leads to replicative advantage towards one particular serotype is a major concern in the development of tetravalent dengue vaccine (Anderson et al., 2011).

Conclusions:

The present study shows that all samples which were able to show PCR amplified product, analysed from the northern Kerala, India between 2013 and 2015 harbour more than one serotype of dengue, indicating 100 % concurrent infection. The occurrence of concurrent infection of DENV 1 and DENV 3 was higher as compared to other combinations. The DENV 1 isolates of Northern Kerala was more closely related to South Korean and Delhi strain based on phylogenetic analysis. Similarly DENV 3 was more closely related to Dengue 3 isolates of Rajasthan, India ((KT239735).

Acknowledgment
We thank Mr. Sebastian, Director at the division of Kanhangad diagnostic centre for providing the clinical samples for research purposes. We also thank all the medical staff and administrative staff of IAD (Institute of Applied Dermatology), Uliyathadka, Kasargod District, Kerala who have kindly assisted in sample processing.

References

1. Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M. (2002) Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1
reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. *J Clin Microbiol* **40**, 376-81.

2. Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL, Sun W. (2011) Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. *J Infect Dis* **204**, 442-50.

3. Anoop M, Issac A, Mathew T, Philip S, Kareem NA, Unnikrishnan R, Sreekumar E. (2010) Genetic characterization of dengue virus serotypes causing concurrent infection in an outbreak in Ernakulam, Kerala, South India. *Indian J Exp Biol* **48**, 849-57.

4. Bharaj P, Chahar HS, Pandey A, Diddi K, Dar L, Guleria R, Kabra SK, Broor S. (2008) Concurrent infections by all four dengue virus serotypes during an outbreak of dengue in 2006 in Delhi, India. *Virol J* **9**, 5:1.

5. Chaturvedi UC, Mathur A, Kapoor AK, Mehrotra NK, Mehrotra RM. (1970) Virological study of an epidemic of febrile illness with haemorrhagic manifestations at Kanpur, India, during 1968. *Bull World Health Organ* **43**, 289-93.

6. Dar L, Gupta E, Narang P, Broor S. (2003) Co-circulation of dengue serotypes, Delhi, India, 2003. *Letter to the editor. Emerg Infect Dis* **12**, 352-353.

7. Deubel V, Laille M, Hugnot JP, Chungue E, Guesdon JL, Drouet MT, Bassot S, Chevrier D. (1990) Identification of dengue sequences by genomic amplification: rapid diagnosis of dengue virus serotypes in peripheral blood. *J Virol Methods* **30**, 41-54.

8. Fatima Z, Idrees M, Bajwa MA, Tahir Z, Ullah O, Zia MQ, Hussain A, Akram M, Khubaib B, Afzal S, Munir S, Saleem S, Rauff B, Badar S, Naudhani M, Butt S, Aftab M, Ali L, Ali M. (2011). Serotype and genotype analysis of dengue virus by sequencing
followed by phylogenetic analysis using samples from three mini outbreaks-2007-2009 in Pakistan. *BMC Microbiol.* **10**;11:200.

9. Gardella-Garcia CE, Perez-Ramirez G, Navarrete-Espinosa J, Cisneros A, Jimenez-Rojas F, Ramirez-Palacios LR, Rosado-Leon R, Camacho-Nuez M, Munoz Mde L. (2008) Specific genetic markers for detecting subtypes of dengue virus serotype-2 in isolates from the states of Oaxaca and Veracruz, Mexico. *BMC Microbiol* **15**, 8:117.

10. Gubler DJ, and Clark, G. G. (1995) Dengue/dengue hemorrhagic fever: the emergence of a global health problem. *Emerg Infect Dis* **1**, 55-7.

11. Gubler DJ, Kuno G, Sather GE, Waterman SH. (1985) A case of natural concurrent human infection with two dengue viruses. *Am Trop Med Hyg* **34**, 170-173.

12. Gubler DJ, Trent DW. (1994) Emergence of epidemic dengue/ dengue hemorrhagic fever as a public health problem in the Americas. *Infect Agents Dis* **2**, 383–393.

13. Gubler DJ. (1998) Dengue and Dengue hemorrhagic fever. *Clin Microbiol, Rev* **11**:480-496.

14. Gupta E, Dar L, Kapoor G, Broor S. (2006) The changing epidemiology of dengue in Delhi, India. *Virology Journal* **3**:92.

15. Holmes EC, Worobey M, Rambaut A. (1999) Phylogenetic evidence for recombination in dengue virus. *Mol Biol Evol* **16**, 405–409.

16. I.M. Rocco, M.L. Barbosa, E.H. Kanomata. (1998) Simultaneous infection with dengue 1 and 2 in a Brazilian patient *Rev. Inst. Med. Trop. Sao Paulo* **40**, 151–154.

17. Kalappanvar NK, VinodKumar CS, Basavarajappa KG, Chandrasekhar G, Sanjay D. (2013) Outbreak of dengue infection in rural Davangere, Karnataka. *Asian Pac J Trop Med* **6**, 502-3.
18. Khan SA, Dutta P, Borah J, Chowdhury P, Doloi PK, Mahanta J. (2013). Dengue outbreak in an Indo-Myanmar boarder area: epidemiological aspects and risk factors. *Trop Biomed.* **30**(3):451-8.

19. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. (1992) Rapid Detection and typing of dengue viruses from clinical samples by using reverse transcriptase polymerase chain reaction. *J Clin Microbiol* **30**, 545-51.

20. Leo YS, Thein TL, Fisher DA, Low JG, Oh HM, Narayanan RL, Gan VC, Lee VJ, Lye DC. (2011). Confirmed adult dengue deaths in Singapore: 5-year multi-center retrospective study. *BMC Infect Dis.* **12**;11:123.

21. Liu-Helmersson J, Stenlund H, Wilder-Smith A, Rocklöv J. (2014) Vectorial capacity of Aedes aegypti: effects of temperature and implications for global dengue epidemic potential. *PLoS One* **9**(3):e89783.

22. M. Laille, V. Deubel, F.F. (1991) Sainte-Marie Demonstration of concurrent dengue 1 and dengue 3 infection in six patients by the polymerase chain reaction. *J. Med. Virol* **34**, 51–54.

23. Mason PW, McAda PC, Mason TL, Fournier MJ. (1987) Sequence of the dengue-1 virus genome in the region encoding the three structural proteins and the major non structural protein NS1. *Virology* **161**, 262-7.

24. Mishra G, Jain A, Prakash O, Prakash S, Kumar R, Garg RK, Pandey N, Singh M. (2015) Molecular characterization of dengue viruses circulating during 2009-2012 in Uttar Pradesh, India. *J Med Virol* **87**, 68-75.

25. Moi ML, Takasaki T, Kurane I. (2016) Human antibody response to dengue virus: implications for dengue vaccine design. *Trop Med Health* **14**, 44:1.
26. Osatomi K, Sumiyoshi H. (1990) Complete nucleotide sequence of dengue type 3 virus genome RNA. *Virology* **176**, 643-7.

27. Sarkar JK, Pavri KM, Chatterjee SN, Chakravarty SK, Aanderson CR. (1964) Virological and serological studies of cases of haemorrhagic fever in Calcutta. *Indian J Med Res* **52**, 684-691.

28. Shah I, Deshpande GC, Tardeja PN. (2004) Outbreak of dengue in Mumbai and predictive markers for dengue shock syndrome. *J Trop Pediatr* **50**, 301-5.

29. Singh J, Balakrishnan N, Bhardwaj M, Amuthadevi P, George EG, Subramani K, Soundararajan K, Appavoo NC, Jain DC, Ichhpujani RL, Bhatia R, Sokhey J. (2000) Silent spread of dengue and dengue haemorrhagic fever to Coimbatore and Erode districts in Tamil Nadu, India, 1998: need for effective surveillance to monitor and control the disease. *Epidemiol Infect* **125**, 195-200.

30. Tamura K., Battistuzzi FU, Billing-Ross P, Murillo O, Filipski A, and Kumar S. (2012) Estimating Divergence Times in Large Molecular Phylogenies. *Proceedings of the National Academy of Sciences* **109**, 19333-19338.

31. Tamura K., Stecher G., Peterson D., Filipski A., and Kumar S. (2013) MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. *Molecular Biology and Evolution* **30**, 2725-2729.

32. W.M.Hammon. (1973) Dengue hemorrhagic fever--do we know its cause? *Am J Trop Med Hyg.* **22**(1):82-91. Review

33. Wenming P, Man Y, Baochang F, Yongqiang D, Tao J, Hongyuan D, Ede Q. (2005) Simultaneous infection with dengue 2 and 3 viruses in a Chinese patient return from Sri Lanka. *J Clin Virol* **32**, 194-198.
34. Worobey M, Rambaut A, Holmes EC. (1999). Widespread intra serotype recombination in natural populations of dengue virus. Proc Natl Acad Sci USA 96:7352-7357.

35. Zhao B, Mackow E, Buckler-White A, Markoff L, Chanock RM, Lai CJ, Makino Y. (1986) Cloning full-length dengue type 4 viral DNA sequences: analysis of genes coding for structural proteins. *Virology* 155, 77-88.
Figure 1

Bar diagram showing the number of dengue virus infected cases under different sex group in three consecutive years (2013-2015).

X - axis represents year of study and Y - axis represents number of dengue infected cases. **A:** Total number of dengue infected individuals. **B, C, D:** Dengue NS1 positive male, female and pediatrics respectively.
Figure 2

Schematic representation of dengue viral CprM junction amplification by RT-PCR.

A) Dengue viral RNA has 5' UTR region, three structural (capsid (C), pre membrane (prM), and envelope (E)) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) genes ends with 3' UTR region. B) CPrM junction (511 bp) of structural region was amplified with D1 and D2 primers using dengue viral RNA as a template. C) The amplified products with D1 and sero specific TS1, TS2, TS3 and TS4 primers independently, indicates the expected size (bp) 482, 119, 290 and 392 respectively by nested PCR.
Figure 3

The agarose gel images (1%) showing the amplified DNA from dengue viral genome using RT-PCR.

Figure A shows a representative DNA gel showing the 511 bp DNA fragment obtained by RT-PCR using dengue viral RNA as template with D1 (forward) and D2 (reverse) primers. Lane 1 and Lane 4 shows the presence of dengue viral genome in the sample as evidenced by a clear DNA band of 511 bp size. However, Lane 2 and 3 did not show the presence of dengue viral genome in the corresponding samples. Figure B, C and D represents DNA gel images showing the nested PCR products by serotype specific primers with D1&TS1 (Lane 1), D1&TS2 (Lane 2), D1&TS3 (Lane 3), D1&TS4 (Lane 4)primer combinations using 511 bp PCR product as a template. In Figure B, Lane 1 and 4 shows the presence of amplified product of size 482 bp and 392 bp respectively indicating the presence of DEV 1 and 4 in the same individual. Similarly, Figure C Shows the presence amplified product of size 482 bp, 119 bp and 290 bp in Lane 1, 2 and 3 respectively, indicating the concurrent infection of dengue serotype 1, 2 and 3 in the same individual. Interestingly, Figure D indicates the concurrent infection of all four serotypes in the same individual as evidenced by the amplified product of size 482 bp, 119 bp 290 bp and 392 bp in all four lanes respectively. M, indicates 1kb DNA ladder (ladder size is shown on the left hand side of Figure A, and lane number indicates on the top of each figure).
Alignment of deduced amino acid sequence of Dengue serotype 1 (DENV 1).

The Amino acid sequence derived from DENV 1 specific amplified region (GenBank accession no.KJ954284) containing 139 amino acid residues were aligned with the other eleven DENV 1 amino acid sequences (GenBank accession no.KP406801, EF127001, DQ285562, JQ922545, JN903581, KM403635, KR024707, KT187563, KP723473, JQ917404, JN713897) of various strains retrieved from GenBank. The gene accession number of individual isolate are shown on the left. The alignment was edited with BioEdit sequence alignment editor. A mutation was observed in the test sample, where Valine was replaced with Isoleucine at 131st position and it was highlighted in the image.
Molecular phylogenetic analysis of DENV 1 by Maximum Likelihood method, Tamura-Nei model.

The phylogenetic tree was constructed from the gene sequences of DENV isolates of different geographical locations and DENV 1 isolate (GenBank accession no.KJ954284) of northern Kerala. The bootstrap support value indicates that the sequence of dengue virus isolate from Northern Kerala shares a close relationship with DENV 1 isolate (GenBank accession no.KP406801) and DENV 1 isolate 06/1/del2006 (GenBank accession no.EF127001). The reliability of the analysis was evaluated by a bootstrap test with 1,000 replications (MEGA 6). The analysis involved total 28 nucleotide sequences.
Figure 6

Molecular phylogenetic analysis of DENV 3 by Maximum Likelihood method, Tamura-Nei model.

The phylogenetic tree was constructed based on dengue gene sequences of different geographical isolates and DENV 3 isolate obtained from northern Kerala (CUKKE2013/02; GenBank accession no. KM042094). The analysis indicates that northern Keralian isolate is closely related to Dengue virus isolate (DENV-3/DMRC/Bal87/2013) polyprotein gene, partial cds (KT239735) of Rajasthan, India. The reliability of the analysis was evaluated by a bootstrap test with 500 replications (MEGA 7), Tamura-Nei model (Tamura et al., 2012).
Table 1 (on next page)

Dengue infected samples analysed during the year 2013-2015.

Total 120 samples were analyzed during the years 2013, 2014 and 2015, out of which 100 samples were NS1 positive. Among the 100 samples, 26 samples were dengue viral RNA positive, out of which, three serotypes (DENV 1, 2 and 3) co-existed in eight samples, two serotypes (DENV 1 and DENV 3) co-existed in nine samples and two serotypes (DENV 2 and DENV 3) co-existed in seven samples and four co-serotypes (DENV 1, 2, 3 and 4) co-existed in two samples. In all cases, multiple infections were observed. However, concurrent infection of all four serotypes was only observed during 2013.
Table 1.

| S.No | Sample description   | 2013 year | 2014 year | 2015 year |
|------|----------------------|-----------|-----------|-----------|
| 1    | Total number of samples | 60        | 20        | 40        |
| 2    | NS1 positive          | 51        | 17        | 32        |
| 3    | NS1 negative          | 9         | 3         | 8         |
| 4    | RNA positive           | 13        | 3         | 10        |
| 5    | Single infection      | NIL       | NIL       | NIL       |
| 6    | Multiple infection    | all       | all       | all       |
| 7    | DENV1 and DENV3       | 4         | 1         | 4         |
| 8    | DENV2 and DENV3       | 2         | 1         | 4         |
| 9    | DENV1,2 and 3         | 5         | 1         | 2         |
| 10   | DENV1,2,3 and 4       | 2         | 0         | 0         |